Stem Cell RegistryAs of today, Geron has nine cell lines, seven of which are listed on the NIH registry (details below). Five of them were derived at the University of Wisconsin-Madison, two are clones of one of the Wisconsin lines and two were derived at the University of California-San Francisco. Geron funded the research by Dr. James Thomson of the University of Wisconsin-Madison in which Dr. Thomson first derived human embryonic stem cells. Geron has a license from the Wisconsin Alumni Research Foundation (WARF) which grants Geron exclusive commercialization rights to three cell types (cardiomyocytes, neural cells and pancreatic islet cells) and non-exclusive rights to three other cell types (hematopoietic cells, osteoblasts and chondrocytes) for therapeutic and diagnostic products; and non-exclusive rights to commercialize research products based on six cell types. Pursuant to Geron's agreement with WARF, Geron may transfer the undifferentiated cell lines only to Geron collaborators for work on projects described and directed by Geron. Geron is committed to the rapid advancement of embryonic stem cell technology, and expects to collaborate with researchers at universities, companies, and other organizations in aggressively pursuing this important technology. We encourage parties interested in discussing possible collaborations to contact: ES Request All other parties interested in obtaining embryonic stem cell lines are encouraged to contact WARF, through its subsidiary WiCell (www.wicell.org). The following embryonic stem cell lines are listed on the NIH Registry.
|
||||||||||||||||||||||||||||||

